Search Results - Keith Dredge

  • Showing 1 - 20 results of 20
Refine Results
  1. 1
    PG545, a Heparan Sulfate Mimetic, Reduces Heparanase Expression In Vivo, Blocks Spontaneous Metastases and Enhances Overall Survival in the 4T1 Breast Carcinoma Model

    PG545, a Heparan Sulfate Mimetic, Reduces Heparanase Expression In Vivo, Blocks Spontaneous Metastases and Enhances Overall Survival in the 4T1 Breast Carcinoma Model by Edward Hammond, Ralf Brandt, Keith Dredge

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues

    Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues by Edward Hammond, Paul Handley, Keith Dredge, Ian Bytheway

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics

    The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics by Edward Hammond, Ashwani Khurana, Viji Shridhar, Keith Dredge

    Published 2014
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy

    Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy by Keith Dredge, Blake J. Marriott, Stephen Todryk, Angus Dalgleish

    Published 2002
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Thalidomide and its analogues have distinct and opposing effects on TNF-<i>α</i>and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells

    Thalidomide and its analogues have distinct and opposing effects on TNF-<i>α</i>and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells by J B Marriott, Ian Clarke, Keith Dredge, George W. Muller, David Stirling, Angus Dalgleish

    Published 2002
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity

    Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity by Keith Dredge, J B Marriott, Stephen Todryk, George W. Muller, Roger Chen, David Stirling, Angus Dalgleish

    Published 2002
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer

    PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer by Katherine T. Ostapoff, Niranjan Awasthi, Bercin Kutluk Cenik, Stefan Hinz, Keith Dredge, Roderich E. Schwarz, Rolf A. Brekken

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation

    Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation by Todd V. Brennan, Liwen Lin, Joshua D. Brandstadter, Victoria R. Rendell, Keith Dredge, Xiaopei Huang, Yiping Yang

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models

    PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models by Keith Dredge, Edward Hammond, Paul Handley, Thomas J. Gonda, Maree T. Smith, Christina Vincent, Ralf Brandt, Vito Ferro, Ian Bytheway

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation

    Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation by Todd V. Brennan, Liwen Lin, Xiaopei Huang, Diana M. Cardona, Zhiguo Li, Keith Dredge, Nelson J. Chao, Yiping Yang

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

    Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects by Keith Dredge, J B Marriott, Claire Macdonald, H‐W Man, R Chen, George W. Muller, David Stirling, Angus Dalgleish

    Published 2002
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors

    Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors by Edward Hammond, Nicole M. Haynes, Carleen Cullinane, Todd V. Brennan, Darryn Bampton, Paul Handley, Tomislav Karoli, Fleur Lanksheer, Liwen Lin, Yiping Yang, Keith Dredge

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

    Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced... by J. Blake Bartlett, A Michael, Ian Clarke, Keith Dredge, Steve Nicholson, Hartmut Kristeleit, A. Polychronis, H. Pandha, George W. Muller, David Stirling, Jerome B. Zeldis, Angus Dalgleish

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

    A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours by Keith Dredge, Todd V. Brennan, Edward Hammond, Jason D. Lickliter, Liwen Lin, Darryn Bampton, Paul Handley, Fleur Lankesheer, Glynn Morrish, Yiping Yang, Michael P. Brown, Michael Millward

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine

    The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine by Deok-Beom Jung, Miyong Yun, Eun-Ok Kim, Jaekwang Kim, Bonglee Kim, Ji Hoon Jung, Enfeng Wang, Debabrata Mukhopadhyay, Edward Hammond, Keith Dredge, Viji Shridhar, Sung‐Hoon Kim

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

    The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells by Christine Galustian, B Meyer, Marie‐Christine Labarthe, Keith Dredge, Deborah Klaschka, Jake Y. Henry, Stephen Todryk, Roger Chen, George W. Muller, David Stirling, Peter Schäfer, J. Blake Bartlett, Angus Dalgleish

    Published 2008
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors

    Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metast... by Charlotte Lemech, Keith Dredge, Darryn Bampton, Edward Hammond, Andrew D. Clouston, Nigel J. Waterhouse, Amanda C. Stanley, Lucie Leveque, Grace Chojnowski, Andrew Haydon, Nick Pavlakis, Matthew Burge, Michael P. Brown, David Goldstein

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples

    PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples by Boris Winterhoff, Luisa Freyer, Edward Hammond, Shailendra Giri, Susmita Mondal, Debarshi Roy, Attila Teoman, Sally A. Mullany, Robert Hoffmann, Antonia von Bismarck, Jeremy Chien, Matthew S. Block, Michael Millward, Darryn Bampton, Keith Dredge, Viji Shridhar

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer

    HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer by Susmita Mondal, Debarshi Roy, Juliana Camacho-Pereira, Ashwani Khurana, Eduardo N. Chini, Lifeng Yang, Joelle Baddour, Katherine Stilles, Seth Padmabandu, Sam Leung, Steve E. Kalloger, C. Blake Gilks, Val J. Lowe, Thomas Dierks, Edward Hammond, Keith Dredge, Deepak Nagrath, Viji Shridhar

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike–ACE2 Interaction

    Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike–ACE2 Interaction by Scott E. Guimond, Courtney J. Mycroft‐West, Neha S. Gandhi, Julia A. Tree, Thuy T. Le, C. Mirella Spalluto, María Victoria Humbert, Karen R. Buttigieg, Naomi S. Coombes, Michael J. Elmore, Matthew E. Wand, Kristina Nyström, Joanna Said, Yin Xiang Setoh, Alberto A. Amarilla, Naphak Modhiran, Julian D. J. Sng, Mohit Chhabra, Paul R. Young, Daniel J. Rawle, Marcelo A. Lima, Edwin A. Yates, Richard Karlsson, Rebecca L. Miller, Yen‐Hsi Chen, Ieva Bagdonaite, Zhang Yang, James P. Stewart, Dung Nguyen, Stephen M. Laidlaw, Edward Hammond, Keith Dredge, Tom Wilkinson, Daniel Watterson, Alexander A. Khromykh, Andreas Suhrbier, Miles W. Carroll, Edward Trybala, Tomas Bergström, Vito Ferro, Mark A. Skidmore, Jeremy E. Turnbull

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: